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Abstract 
Introduction: 
Based on the World Health Organization reports, infections caused by ampicillin-resistant 
Haemophilus influenzae strains are a major threat to public health and need urgent therapy with new 
antibiotics. Given the lack of a previous comprehensive study on the prevalence of the antibiotic 
resistance of H. influenzae in Iran, this systematic review and meta-analysis was performed to 
increase the knowledge about antibiotic resistance status of this pathogenic agent. 
 
Materials and Methods:  
For the purpose of the study, the articles related to the subject of interest and published up to August 
2018 were searched in several English and Persian databases, including PubMed, Scopus, Web of 
Science, Scientific Information Database, and Magiran. The search process was accomplished using 
the following keywords: “Antibiotic resistance”, “H. influenzae”, and “Iran”. The data were pooled 
from 13 eligible studies reporting the prevalence of antibiotic resistance of H. influenzae in Iran. 
  
Results:  
The prevalence of H. influenzae resistance to various antibiotics in Iran, including ampicillin, 
amoxicillin, cephalexin, cefixime, ceftazidime, cefotaxime, and ceftizoxime, were obtained as 54.8%, 
66.6%, 28.6%, 62%, 21.3%, 22.3%, 23.2%, respectively.These rates were reported as 27.7%, 46.7%, 
53%, 82.6%, 40.3%, 30.8% for chloramphenicol, tetracycline, trimethoprim/sulfamethoxazole, 
penicillin, erythromycin, and ciprofloxacin, respectively. Additionally, ceftriaxone, gentamicin, 
amikacin, kanamycin, rifampin, azithromycin, and clindamycin had the H. influenzae resistance rates of  
33.1%, 40.2%, 45.8%, 44.4%, 18.5%, 17.4%, and 71.3%, respectively.  
 
Conclusion: 
The majority of the antibiotics tested in Iran showed a high rate of resistance to H. influenzae. This 
may cause serious problems in the treatment of infections in the future. Therefore, precautionary 
measures, such as monitoring antibiotic prescription and resistance and using the new classes of 
antibiotics, are necessary. 
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Introduction 
Members of Haemophilus genus are small, 
non-motile, Gram-negative rods or coccobacilli 
(pleomorphic), and facultative anaerobic 
bacteria which are classified in the family 
Pasteurellaceae (1,2). Haemophilus influenzae 
is the most common Haemophilus species 
infecting human, as the only known reservoir, 
which exists asymptomatically in the naso- and 
oro-pharynx of healthy carriers (1-3). Its 
primary colonization occurs through binding to 
the mucous membranes of the upper respiratory 
tract where the bacterium interferes with the 
ciliary motion. Therefore, the major 
transmission route of this species is through the 
respiratory tract (1-5).  
Based on a polysaccharide capsule antigen, 
bacteria can be divided into encapsulated and 
noncapsulated/nontypeable (NTHi) strains. In 
addition, the encapsulated isolates can be 
categorized into six antigenic serotypes (a-f)  
(1-5). Encapsulated and nonencapsulated H. 
influenzae are responsible for several life-
threatening invasive infections in children and 
adults. Some of these infections include acute 
bacterial meningitis, epiglottitis, pneumonia, 
bacteremia/sepsis, septic arthritis, otitis media, 
sinusitis, and cellulitis (1-5). 
Haemophilus influenzae type b (Hib) is a 
common cause of severe diseases, almost 
exclusively among children under the age of 5 
years. According to the World Health 
Organization (WHO) estimates performed in 
March 2012, Hib is responsible for 2% of all-
cause child mortality and 199,000 deaths per 
year (6,7). A high morbidity rate in untreated 
patients, as well as serious neurologic sequelae, 
which is particularly due to H. influenzae 
meningitis or epiglottitis, calls for proper 
diagnosis and treatment with antimicrobial 
agents (1,2,5). The important antibiotics applied 
in the treatment of less severe H. influenzae 
infections include amoxicillin, cephalosporin, 
azithromycin, doxycycline, and 
fluoroquinolone. However, serious infections 
are managed by broad-spectrum cephalosporins 
and carbapenems (1,2). Additionally, rifampin 
is the drug of choice for antibiotic prophylaxis 
in children carrying Hib (2). Nonetheless, 
WHO has recently placed ampicillin-resistant 
H. influenzae strains, along with penicillin-
resistant Streptococcus pneumoniae and 
fluoroquinolone-resistant Shigella strains, in the 
list of antibiotic-resistant bacteria and medium 
priority category, in terms of the emergency of 
developing new antibiotics (8). Therefore, 
assessing antimicrobial susceptibility patterns 
and monitoring the resistance trend of H. 
influenzae are essential to guide prior antibiotic 
choice and prescription at the local level, 
thereby reducing the risk of treatment failure. 
With this background in mind, the present study 
was conducted to review the evidence on the 
antimicrobial susceptibility patterns of H. 
influenzae strains to different antibiotics in Iran 
through a systematic review and meta-analysis. 
 
Materials and Methods 
Search strategies 
To find all reports on the prevalence of the 
antibiotic resistance of H. influenzae in Iran, 
the related studies published up to August 
2018 were searched in several electronic 
databases, including PubMed, Scopus, Web of 
Science, Scientific Information Database 
(SID), and Magiran. “Antibiotic resistance”, 
“H. influenzae”, and “Iran” were the most 
important MeSH-extracted keywords. In 
addition, the manual search of the 
bibliographies was performed to avoid missing 
any relevant articles. This systematic review 
and meta-analysis was performed in 
accordance with the Preferred Reporting Items 
for Systematic reviews and Meta-Analyses 
(PRISMA) checklist (9). 
 
Selection of articles 
Screening of the articles was performed in 
three steps by two independent authors based 
on the defined inclusion and exclusion criteria. 
The titles, abstracts, and full texts of the 
articles were sequentially reviewed (Fig.1).  
 
Fig 1: Schematic representation of the article 
selection process. 
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All kinds of articles that were published in 
English or Persian languages (with the 
exception of review articles and duplicates) 
and reported on the antibiotic resistance of H. 
influenzae in Iran were included in the study. 
According to the Newcastle-Ottawa quality 
assessment scale criteria adapted for cross-
sectional studies, a quality assessment of the 
included studies was performed on the meta-
analysis, and high-quality studies received 5 or 
more stars. 
 
Data extraction  
Data collection process from eligible studies 
was performed in duplicate (Table.1). The 
main extracted data from the included studies 
were the year of study, city, number of 
isolated H. influenzae strains, antibiotic 
susceptibility testing methods, and number of 
resistant strains to different antibiotics. 
 
Meta-analysis 
Quantitative data synthesis was performed 
using Comprehensive Meta-Analysis software 
(version 2.2; Biostat, Englewood, NJ). The rate 
of H. influenzae antimicrobial resistance was 
reported as percentage and 95% confidence 
intervals (95% CIs) using fixed- or the random-
effects models. In case of observing a high 
heterogeneity (I
2
 statistic>25% and P<0.1) 
among the included studies, a random-effects 
model was applied. Begg’s funnel plot 
asymmetry was explored for the presence of 
potential publication bias. In addition, the 
existence of heterogeneity was evaluated using 
I
2
 statistic and the Cochrane Q statistic.  
 
Results 
Characteristics of the included studies 
In the present study, a total of 43 articles were 
collected from different databases and the 
reference lists. The selection process of the 
studies is illustrated in Figure 1. After screening 
studies based on the inclusion and exclusion 
criteria, 13 eligible articles were included in the 
meta-analysis. These studies had been 
conducted in Ahwaz, Hamadan, Karadj, 
Mashhad, Qazvin, Shahrekord, Shiraz, Tehran, 
and Tabriz in Iran (Table.1). As shown in the 
funnel plot, there was a possibility of 
publication bias in the eligible articles 
evaluating the prevalence of H. influenzae 
resistance to ampicillin. Similarly, the funnel 
plot was found to be asymmetric for many other 
antibiotics. Microbiological identification 
methods which were used for bacterial isolation 
from different specimens, such as cerebrospinal 
fluid, nasopharynx, and blood, were based on 
growth on chocolate agar medium at 37°C for 
24-48 h in a candle jar, growth requirement for 
X (hemin) and V (NAD) factors, carbohydrate 
fermentation reactions, serological tests for 
serotyping, and biochemical tests for biotyping 
(e.g., oxidase, catalase, urea, indole, and 
ornithine decarboxylase). 
  
Characteristics of Haemophilus influenzae 
antibiotic resistance 
Most of the studies included in this review 
used Kirby-Bauer's disk diffusion method to 
determine the antimicrobial susceptibility of 
H. influenzae in Iran. In the present study, we 
observed a high degree of heterogeneity 
among the included studies when pooling data. 
Therefore, the prevalence of H. influenzae 
antibiotic resistance was evaluated using a 
random-effects model for most of the drugs. 
Haemophilus influenzae resistance rates to 
various antibiotics were as follows: 54.8% for 
ampicillin (95% CI: 40-68.7; I
2 
=73.7%; Q=38; 
df (Q)=10; P=0.00), 66.6% for amoxicillin 
(95% CI: 43.6-83.7; I
2
=72.6%; Q=21.9; df 
(Q)=6; P=0.00), 28.6% for cephalexin (95% CI: 
14.5-48.7; I
2
=0.0%; Q=1.6; df (Q)=2; P=0.43), 
62% for cefixime (95% CI: 51.3-71.6; 
I
2
=25.2%; Q=5.3; df (Q)=4; P=0.25), 21.3% for 
ceftazidime (95% CI: 8.3-45; I
2
=75.9%; Q=8.3; 
df (Q)=2; P=0.01), 22.3% for cefotaxime (95% 
CI: 12.1-37.3; I
2
=0.0%; Q=1.7; df (Q)=2; 
P=0.41), 23.2% for ceftizoxime (95% CI: 16.4-
31.8; I
2
=9%; Q=5.5; df (Q)=5; P=0.35), 27.7% 
for chloramphenicol (95% CI: 7.2-65.3; 
I
2
=73.8%; Q=22.9; df (Q)=6; P=0.00), 46.7% 
for tetracycline (95% CI: 17.8-78; I
2
=74.1%; 
Q=11.5; df (Q)=3; P=0.00), 53% for 
trimethoprim/sulfamethoxazole (95% CI: 36.1-
69.3; I
2
=78.7%; Q=51.7; df(Q)=11; P=0.00), 
82.6% for penicillin (95% CI: 75.2-88.2; 
I
2
=0.0%; Q=0.1; df (Q)=2; P=0.91), 40.3% for 
erythromycin (95% CI: 7.6-84.6; I
2
=74.1%; 
Q=7.7; df (Q)=2; P=0.02), 30.8% for 
ciprofloxacin (95% CI: 9.5-65.4; I
2
=68.4%; 
Q=9.4; df (Q)=3; P=0.02), 33.1% for 
ceftriaxone (95% CI: 19.5-50.4; I
2
=39.5%; 
Q=6.6; df (Q)=4; P=0.15), 40.2% for 
gentamicin (95% CI: 14.4-72.9; I
2
=74%; 
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Q=19.2; df (Q)=5; P=0.00), 45.8% for amikacin 
(95% CI: 24.9-68.2; I
2
=51.6%; Q=6.2; df 
(Q)=3; P=0.10), 44.4% for kanamycin (95% CI: 
7.3-89; I
2
=77.9%; Q=13.5; df (Q)=3; P=0.00), 
18.5% for rifampin (95% CI: 7.4-39.3; 
I
2
=66.1%; Q=2.9; df (Q)=1; P=0.08), 17.4% for 
azithromycin (95% CI: 10.2-28.3; I
2
=0.0%; 
Q=0.9; df (Q)=1; P=0.34), and 71.3% for 
clindamycin (95% CI: 20.1-96.1; I
2
=84.6%; 
Q=13; df (Q)=2; P=0.00; Table.2). 
Additionally, other antibiotic resistance patterns 
were as follow: 6 (85%) for vancomycin, 7 
(50%) for cefazolin, 6 (45.8%) for cephradine, 
1 (25%) for ofloxacin, 0 (0%) for imipenem, 2 
(100%) for cloxacillin, 9 (47.4%) for 
cephalothin, 16 (84.4%) for tobramycin, 6 
(11.8%) for amoxicillin/clavulanic acid, 7 
(13.7%) for cefuroxime, 18 (35.3%) for 
clarithromycin, and 3 (43%) for doxycycline. 
 
Discussion 
According to the previous systematic reviews 
and meta-analysis, the most frequent causes of 
bacterial meningitis in Iran are Streptococcus 
pneumoniae, Hib, coagulase-negative 
staphylococci, and Neisseria meningitidis, 
respectively (23,24). In many countries, the 
introduction of conjugate Hib vaccines given 
during early infancy has led to reduced 
mortality rates, especially in children under 5 
years of age living in developing countries 
(7,25). However, Hib vaccine is not 
compulsory in the vaccination program of Iran 
(25). Accordingly, bacterial meningitis is a 
health problem, especially in children in Iran, 
which requires antimicrobial treatment (12). 
The recommended empirical antibiotic therapy 
for bacterial meningitis in children and 
newborns is vancomycin plus cefotaxime or 
ceftriaxone (7,26). In the present study, the 
prevalence rates of vancomycin-, cefotaxime- 
and ceftriaxone-resistant H. influenzae strains 
in Iran were 85%, 22.3%, and 33.1%, 
respectively (Table.2). Additionally, 
chloramphenicol, cefepime, and meropenem are 
considered as alternative regimens (7,26).  
In Iran, the prevalence of chloramphenicol-
resistant H. influenzae strains was 27.7%, and 
the rate of cefepime- and meropenem-resistant 
H. influenzae strains were not determined 
(Table.2). Furthermore, another alternative 
regimen is ampicillin plus cefepime or 
chloramphenicol for ampicillin-susceptible 
strains (7,26). The prevalence of H. influenzae 
strains resistant to ampicillin was estimated at 
54.8% (Table.2 and Fig.2).  
 
Fig 2: Forest plot of the meta-analysis of the 
prevalence of H. influenzae resistance to ampicillin 
in Iran. 
 
Fig 3: Funnel plot of the meta-analysis of the 
prevalence of H. influenzae resistance to ampicillin 
in Iran. 
Fluoroquinolone antibiotics are also 
recommended for adult patients (7,26). 
According to our results, 30.8% and 25% of H. 
influenzae strains were resistant to 
ciprofloxacin and ofloxacin, respectively. 
After meningitis, childhood pneumonia and 
bacteremia are the most common diseases 
caused by Hib strains, and pneumonia is 
particularly dominant in developing countries 
(27). Amoxicillin or amoxicillin/clavulanic acid 
(co-amoxiclav) are recommended for 
outpatients. Furthermore, ceftriaxone or 
cefotaxime are suggested for inpatients with 
pediatric pneumonia empirical therapies (7,28). 
Ceftriaxone, cefotaxime, or cefuroxime are also 
suggested for the treatment of pneumonia and 
bacteremia caused by β-lactamase-producing H. 
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influenzae strains. On the other hand, ampicillin 
is suggested for β-lactamase-negative strains  
(7,28). The prevalence rates of H. influenzae 
strains resistant to amoxicillin, amoxicillin/ 
clavulanic acid, and cefuroxime in Iran were 
66.6%, 11.8%, and 13.7%, respectively. 
Untypeable H. influenzae is responsible for 2-
12% of community-acquired pneumonia. The 
recommended antibiotics for this strain are 
azithromycin, clarithromycin, and doxycycline 
(7). Azithromycin and clarithromycin are also 
alternative treatments in patients with acute 
otitis media who have penicillin allergy. Based 
on the evidence, 23-67% of acute otitis media 
cases are caused by untypeable H. influenzae 
(7,29). In Iran, 17.4%, 35.3%, and 43% of H. 
influenzae strains were reported to be resistant 
to azithromycin, clarithromycin, and 
doxycycline, respectively. Trimethoprim-
sulfamethoxazole, erythromycin, rifampin, and 
cefixime, along with many other antibiotics, 
were used to treat acute sinusitis caused by 
untypeable H. influenzae in adult and pediatric 
patients (7). In the present study, the prevalence 
rates of H. influenzae strains resistant to 
trimethoprim-sulfamethoxazole, erythromycin, 
rifampin, and cefixime were 53%, 40.3%, 
18.5%, and 62%, respectively.  
Our results were compared with those of other 
studies performed in other countries. In this 
regard, H. influenzae antibiotic resistance rate 
to ampicillin in Iran (54.8%) was found to be 
higher than those reported for Lebanon 
(17.4%), France (43%), Germany (20.1%), Italy 
(11.4%), Mexico (27.4%), and South Africa, 
Spain, and United States (0%) (5,30). 
Furthermore, the antibiotic resistance rates of 
H. influenzae to amoxicillin-clavulanate 
(11.8%), azithromycin (17.4%), and ceftriaxone 
(33.1%) were higher in comparison to those 
reported in Turkey (azithromycin: 0%), Korea 
(amoxicillin-clavulanate: 10.4%), and France, 
Germany, Italy, Mexico, South Africa, Spain, 
and United States (0%) (5,31,32).  
Clarithromycin (35.3%), chloramphenicol 
(27.7%), trimethoprim/sulfamethoxazole 
(53%), and cefotaxime (22.3%) had higher 
resistance rates in Iran than in Lebanon, Korea, 
Turkey, North America, Latin America, and 
Europe (5,30-32). Similarly, antibiotic 
resistance rates to quinolones, ciprofloxacin 
(30.8%), and ofloxacin (25%) were higher than 
those reported in Lebanon, North America, 
Latin America, and Europe (5,30). The H. 
influenzae antibiotic resistance rates to rifampin 
(18.5%) and tetracycline (46.7%) were higher 
as compared to those in Lebanon and Spain  
(30,33). Finally, antibiotic resistance rates to 
gentamicin, amikacin, and kanamycin were 
higher than that reported for Lebanon (30), 
while resistance to ampicillin and cefuroxime 
was lower than that of Korea (32). 
The initial origin of many antibiotic-resistant 
strains, such as sulfonamide-resistant 
Streptoccoccus pyogenes, penicillin-resistant 
Staphylococcus aureus, and streptomycin-
resistant Mycobacterium tuberculosis, were 
hospitals, where drugs are used extensively 
(34). Such bacteria, along with the emergence 
of multidrug-resistant strains, have become a 
health concern and led to treatment failure and 
increased healthcare costs, especially in 
developing countries where antibiotics are 
available without a prescription (34). Therefore, 
it is essential to manage and prevent drug 
resistance by tracking drug resistance rates at 
national and international levels. Isolation of 
individuals in hospitals who are infected with 
difficult-to-treat bacterial agents is another 
measure to prevent the spread of resistant 
strains in hospitals and communities. Finally, 
the provision of rapid diagnostic and new 
therapeutic methods (e.g., reduced or careful 
use of current antibiotics and development of 
new antimicrobials and vaccines) are necessary 
to control the spread of antibiotic-resistant 
strains (34). 
 
Conclusion 
The results of the reviewed studies were 
indicative of an alarming trend in H. 
influenzae resistance to the majority of 
antibiotic drugs tested in Iran. Continuation of 
this trend will reduce therapeutic options and 
complicate the successful management of H. 
influenzae infections. Therefore, several 
precautionary measures are essential to be 
implemented. Some of these measures include: 
1) creating a strong surveillance system in 
order to allow continuous monitoring of drug 
resistance, 2) enhancing physicians’ awareness 
about drug resistance trends and avoiding 
prescribing antibiotics with a high resistance 
rate, 3) informing patients about drug 
resistance trends in order to avoid misusing 
antibiotics to prevent the prevalence of 
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antibiotic-resistant pathogens, 4) further 
investigating the resistance mechanisms of H. 
influenzae against different antimicrobial 
agents in Iran, and 5) performing continuous 
antimicrobial susceptibility tests to select the 
most effective drugs or use new antibiotics.  
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Table 1: Profiles of the studies included in the meta-analysis 
Author (Ref) Year City Strain (n) AST 
Antibiotic resistance (n) 
AMP AMX LEX CFM CAZ CTX ZOX CHL TET TMP-SMX PEN ERY CIP CRO GEN AMK KAN RIF AZM CLI 
Farajzadeh (10) 2000-2001 Ahwaz 14 ND 3 4 5 ND ND 2 3 1 2 8 ND ND ND ND ND ND ND ND ND ND 
Mashouf  (11) 1998-2002 Hamadan 6 
Disk 
diffusion 
3 3 0 ND ND ND 0 0 ND 3 ND ND ND ND 0 ND 0 ND ND ND 
Mojgani (12) ND Karadj 38 ND 17 ND ND ND ND ND ND ND 15 18 ND ND ND ND ND ND ND ND ND ND 
Ghazvini (13) 2004-2005 Mashhad 125 
Disk 
diffusion 
88 99 ND 72 ND ND ND ND ND 89 103 22 ND ND ND ND ND ND ND ND 
Moafi (14) 2013-2014 Qazvin 8 
Disk 
diffusion 
4 4 2 ND ND ND 2 1 ND 4 ND ND ND ND 1 ND 1 ND ND ND 
Imani (15) 2005 Shahrekord 4 
Broth micro 
dilution 
4 ND ND ND ND ND ND ND ND ND 4 1 1 1 ND ND ND ND ND ND 
Shishegar (16) 2007-2008 Shiraz 6 
Disk 
diffusion 
6 6 ND 6 ND 0 ND ND ND 6 ND 6 4 0 ND ND ND ND ND ND 
Boroumand (17) ND Tehran 20 
Disk 
diffusion 
ND 19 ND ND ND ND ND 20 20 0 ND ND 9 10 ND ND ND ND 2 20 
Kalantari(18) 1995-2005 Tehran 2 
Disk 
diffusion 
2 ND ND ND ND ND ND 2 ND 2 2 ND ND ND 2 2 2 ND ND ND 
Fahimzad (19) 2005 Tehran 51 
Disk 
diffusion 
17 ND ND 30 5 ND 9 ND ND 45 ND ND ND ND ND ND ND 6 10 15 
Haghi (20) 2001-2007 Tehran 19 
Disk 
diffusion 
8 ND ND 8 8 ND 8 7 ND 10 ND ND ND 8 12 10 16 ND ND ND 
Dallal (21) ND Tehran 7 
Disk 
diffusion 
ND 4 ND 5 ND ND ND ND 3 0 ND ND ND ND 6 4 ND ND ND 5 
Abdinia (22) 2003-2013 Tabriz 25 
Disk 
diffusion 
19 ND ND ND 5 7 5 0 ND 5 ND ND 1 5 4 6 ND 7 ND ND 
Abbreviations: AMP: ampicillin, AMX: amoxicillin, LEX: cephalexin, CFM: cefixime, CAZ: ceftazidime, CTX: cefotaxime, ZOX: ceftizoxime, CHL: chloramphenicol, TET: tetracycline, TMP/SMX: trimethoprim/sulfamethoxazole, PEN: penicillin, ERY: erythromycin, CIP: 
ciprofloxacin, CRO: ceftriaxone, GEN: gentamicin, AMK: amikacin, KAN: kanamycin, RIF: rifampin, AZM: azithromycin, CLI: clindamycin, AST: antimicrobial susceptibility testing, ND: not determined, CSF: cerebrospinal fluid 
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Table 2: Antimicrobial susceptibility pattern of H. influenzae in Iran. 
Province Antibiotic resistance (%)(95% CI) 
 AMP AMX LEX CFM CAZ CTX ZOX CHL TET TMP-SMX PEN ERY CIP CRO GEN AMK KAN RIF AZM CLI 
Ahwaz 
21.4 
(7.1-49.4) 
28.6 
(11.1-56.1) 
35.7 
(15.7-62.4) 
ND ND 
14.3 
(3.6-42.7) 
21.4 
(7.1-49.4) 
7.1 
(1-37) 
14.3 
(3.6-42.7) 
57.1 
(31.6-79.4) 
ND ND ND ND ND ND ND ND ND ND 
Hamadan 
50 
(16.8-83.2) 
50 
(16.8-83.2) 
0 ND ND ND 0 0 ND 
50 
(16.8-83.2) 
ND ND ND ND 0 ND 0 ND ND ND 
Karaj 
44.7 
(29.9-60.5) 
ND ND ND ND ND ND ND 
39.5 
(25.4-55.6) 
47.4 
(32.3-63) 
ND ND ND ND ND ND ND ND ND ND 
Mashhad 
70.4 
(61.8 -77.7) 
79.2 
(71.2-85.4) 
ND 
57.6 
(48.8-66) 
ND ND ND ND ND 
71.2 
(62.7-78.5) 
82.4 
(74.7-88.1) 
17.6 
(11.9-25.3) 
ND ND ND ND ND ND ND ND 
Qazvin 
50 
(20-80) 
50 
(20-80) 
25 
(6.3-62.3) 
ND ND ND 
25 
(6.3-62.3) 
12.5 
(1.7-53.7) 
ND 
50 
(20-80) 
ND ND ND ND 
12.5 
(1.7-53.7) 
ND 
12.5 
(1.7-53.7) 
ND ND ND 
Shahrekord 
90 
(32.6-99.4) 
ND ND ND ND ND ND ND ND ND 
90 
(32.6-99.4) 
25 
(3.4-76.2) 
25 
(3.4-76.2) 
25 
(3.4-76.2) 
ND ND ND ND ND ND 
Shiraz 
92.9 
(42.3-99.6) 
92.9 
(42.3-99.6) 
ND 
92.9 
(42.3-99.6) 
ND 0 ND ND ND 
92.9 
(42.3-99.6) 
ND 
92.9 
(42.3-99.6) 
66.7 
(26.8-91.6) 
0 ND ND ND ND ND ND 
Tehran 
37.1 
(26.6-48.9) 
82.2 
(25.5-98.4) 
ND 
55.7 
(44.4-66.5) 
22 
(4.2-64.5) 
ND 
27.6 
(10.4-55.8) 
79.4 
(19.8-98.4) 
82.2 
(8.5-99.6) 
43.5 
(11-82.7) 
83.3 
(19.4-99) 
ND 
45 
(25.3-66.4) 
46.2 
(31.3-61.7) 
69.1 
(49.6-83.6) 
56 
(37.6-72.9) 
84.1 
(62.8-94.3) 
11.8 
(5.4-23.8) 
17.4 
(10.2-28.3) 
71.3 
(20.1-
96.1) 
Tabriz 
76 
(55.8-88.8) 
ND ND ND 
20 
(8.6-40) 
28 
(14-48.2) 
20 
(8.6-40) 
0 ND 
20 
(8.6-40) 
ND ND 
4 
(0.6-23.5) 
20 
(8.6-40) 
16 
(6.1-35.7) 
24 
(11.2-44.2) 
ND 
28 
(14-48.2) 
ND ND 
Total 
54.8 
(40-68.7) 
66.6% 
(43.6-83.7) 
28.6 
(14.5-48.7) 
62 
(51.3-71.6) 
21.3 
(8.3-45) 
22.3 
(12.1-37.3) 
23.2 
(16.4-31.8) 
27.7 
(7.2-65.3) 
46.7 
(17.8-78) 
53 
(36.1-69.3) 
82.6 
(75.2-88.2) 
40.3 
(7.6-84.6) 
30.8 
(9.5-65.4) 
33.1 
(19.5-50.4) 
40.2 
(14.4-72.9) 
45.8 
(24.9-68.2) 
44.4 
(7.3-89) 
18.5 
(7.4-39.3) 
17.4 
(10.2-28.3) 
71.3 
(20.1-
96.1) 
AMP: ampicillin, AMX: amoxicillin, LEX: cephalexin, CFM: cefixime, CAZ: ceftazidime, CTX: cefotaxime, ZOX: ceftizoxime, CHL: chloramphenicol, TET: tetracycline, TMP/SMX: trimethoprim/sulfamethoxazole, PEN: penicillin, ERY: erythromycin, CIP: ciprofloxacin, CRO: 
ceftriaxone, GEN: gentamicin, AMK: amikacin, KAN: kanamycin, RIF: rifampin, AZM: azithromycin, CLI: clindamycin, ND: not determined 
 
 
